ClinicalTrials.gg
CompletedNCT00827112Updated Jun 15, 2012Results posted

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

A Phase 2 interventional study of maraviroc and maraviroc in Human Immunodeficiency Virus-1, sponsored by ViiV Healthcare. Completed at 39 sites in 3 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2012-06-15.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

This is a pilot study to examine if the novel treatment regimen maraviroc plus boosted atazanavir can be expected to be safe and efficacious in treatment naive HIV infected patients. Based on the results from this study, a confirmatory phase 3 study may be conducted.

02

Conditions studied

  • Human Immunodeficiency Virus-1

Keywords

  • CCR5-tropic HIV-1 virus
03

In context

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -1 RNA viral load of ≥1,000 copies/mL measured at the Screening Visit.
  • ≥100 cells/mm3 at Screening.
  • Have only R5 HIV-1 at Screening as verified by the Monogram Bioscience Trofile® assay with enhanced sensitivity.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any other antiretroviral therapy for more than 14 days at any time.
  • Any evidence of resistance to atazanavir, tenofovir, and emtricitabine.
  • X4-or dual/mixed-tropic virus by enhanced Trofile assay or repeated assay failure or not reportable results.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Arm A

    maraviroc (Selzentry, Celsentri) 150 mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100mg QD Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir (Reyataz) in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir (Prezista)/ritonavir (Norvir)((800/100 mg) QD or lopinavir/ritonavir (Kaletra, Aluvia)(400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir (Prezista)/ritonavir (Norvir) or lopinavir/ritonavir (Kaletra, Aluvia)(, then the subject must be discontinued from the study.

    Drug: maraviroc

  • Experimental
    Arm B

    emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir/ritonavir (800/100 mg) QD or lopinavir/ritonavir (400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir/ritonavir or lopinavir/ritonavir, then the subject must be discontinued from the study.

    Drug: maraviroc

Interventions

  • maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR maraviroc (Selzentry, Celsentri) 150mg QD+ lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))

    Also known as: maraviroc =Celsentri, Selzentry; atazanavir =Reyataz; ritonavir =Norvir; lopinavir/ritonavir=Kaletra, Aluvia; darunavir=Prezista

  • emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + lopinavir/ritonavir(Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))

    Also known as: maraviroc=Celsentri, Selzentry; emtricitabine/tenofovir=Truvada; atazanavir =Reyataz; ritonavir =Norvir; lopinavir/ritonavir=Kaletra, Aluvia

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Plasma Human Immuno Deficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than 50 Copies/Milliliter (mL)

    Time frame: Week 48

Secondary outcomes

  1. HIV-1 RNA Levels at Baseline

    Time frame: Baseline

  2. Change From Baseline in HIV-1 RNA Levels of First 15 Participants at Days 4, 7, 10 and 14

    Plasma HIV-1 RNA levels were evaluated for first 15 participants enrolled at United States (U.S) sites only.

    Time frame: Baseline , Days 4, 7, 10 and 14

  3. Maximum Observed Plasma Concentration (Cmax) of Maraviroc

    Time frame: Day 14 (0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose)

  4. Minimum Observed Plasma Concentration (Cmin) of Maraviroc

    Time frame: Day 14 (0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose)

  5. Average Observed Plasma Concentration (Cavg) of Maraviroc

    Cavg was described as area under the plasma concentration-time profile from time zero to time 24 hours (AUC24) divided by the dosing interval (AUC24/ 24).

    Time frame: Day 14 (0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose)

  6. Change From Baseline in Plasma log10 Viral Load at Weeks 16, 24, 48 and 96

    Time frame: Baseline, Week 16, Week 24, Week 48, Week 96

  7. Percentage of Participants With Less Than 50 Copies/mL of HIV-1 RNA

    Time frame: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, Week 96

  8. Percentage of Participants With Less Than 400 Copies/mL of HIV-1 RNA

    Time frame: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, Week 96

  9. Time to Loss of Virological Response (TLOVR)

    TLOVR (virological failure) was defined as the time from first dose of study treatment (Day 1) until the time of virologic failure using the time to loss of virologic response algorithm.

    Time frame: Baseline through Week 96

  10. Time-Averaged Difference (TAD) in log10 Viral Load

    TAD was calculated as area under the curve of HIV divided by time period minus baseline HIV where HIV was denoted as HIV-1 RNA (log10 copies/mL).

    Time frame: Week 16, Week 24, Week 48, Week 96

  11. Change From Baseline in Cluster of Differentiation 4+T Lymphocyte (CD4) Cell Counts at Weeks 16, 24, 48 and 96

    Time frame: Baseline, Week 16, Week 24, Week 48, Week 96

  12. Change From Baseline in Cluster of Differentiation 8+T Lymphocyte (CD8) Cell Count at Weeks 16, 24, 48 and 96

    Time frame: Baseline, Week 16, Week 24, Week 48, Week 96

  13. Number of Participants With Genotypic Resistance

    Genotypic resistance was assessed for all participants at screening and was evaluated for protease inhibitors (PIs), Nucleotide reverse transcriptase inhibitors (NRTIs), and non-NRTIs (NNRTIs) using Monogram GenoSeq and/or PhenoSenseGT assays. This was then repeated for all participants with HIV-1 viral load more than 500 copies/mL either at treatment failure or at early termination, up to Week 96.

    Time frame: Week 96 or Time of treatment failure

  14. Number of Participants With Phenotypic Resistance

    Phenotypic resistance was assessed for all participants at screening and was evaluated for PIs, NRTIs, and NNRTIs using Monogram GenoSeq and/or PhenoSenseGT assays. This was then repeated for all participants with HIV-1 viral load more than 500 copies/mL either at treatment failure or at early termination, up to Week 96.

    Time frame: Week 96 or Time of treatment failure

  15. Number of Participants With HIV-1 RNA Tropism Status Using Trofile Assay

    Viral tropism was determined using the trofile assay with enhanced sensitivity for participants with HIV-1 RNA greater than equal to 1000 copies/mL. The enhanced trofile assay had the sensitivity to detect 100 percent of spiked samples when C-X-C chemokine receptor type 4 {CXCR4} \[X4\]-using HIV-1 RNA represented 0.3 percent of the total viral population.

    Time frame: Baseline to Week 96 or Time of treatment Failure

07

Results

Posted Nov 24, 2011

Participant flow

Participant flow — Overall Study
MilestoneMaraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / Tenofovir
Started6564
Treated6061
Completed5052
Not completed1512
Withdrew: Adverse event20
Withdrew: Lack of efficacy20
Withdrew: Lost to follow-up32
Withdrew: Pregnancy01
Withdrew: Protocol violation02
Withdrew: Withdrawal by subject21
Withdrew: Randomized but not treated53
Withdrew: Other13

Outcome measures

PrimaryPercentage of Participants With Plasma Human Immuno Deficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than 50 Copies/Milliliter (mL)
Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma Human Immuno Deficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than 50 Copies/Milliliter (mL)
Percentage of participantsMaraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / Tenofovir
Percentage of Participants With Plasma Human Immuno Deficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than 50 Copies/Milliliter (mL)74.60 (63.47 to 85.69)83.60 (74.32 to 92.90)
SecondaryHIV-1 RNA Levels at Baseline
Time frame:
Baseline
Reported as:
Mean · copies/mL
HIV-1 RNA Levels at Baseline
copies/mLMaraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / Tenofovir
HIV-1 RNA Levels at Baseline84982 ± 127008114827 ± 149638
SecondaryChange From Baseline in HIV-1 RNA Levels of First 15 Participants at Days 4, 7, 10 and 14

Plasma HIV-1 RNA levels were evaluated for first 15 participants enrolled at United States (U.S) sites only.

Time frame:
Baseline , Days 4, 7, 10 and 14
Reported as:
Mean · copies/mL
Change From Baseline in HIV-1 RNA Levels of First 15 Participants at Days 4, 7, 10 and 14
copies/mLMaraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / Tenofovir
Change at Day 41800.00 ± 37351.09-46479.40 ± 62259.15
Change at Day 7-36947.90 ± 28463.80-52137.10 ± 68684.14
Change at Day 10-58595.80 ± 66157.66-54925.90 ± 70846.93
Change at Day 14-47271.60 ± 38234.34-55449.90 ± 71207.16
SecondaryMaximum Observed Plasma Concentration (Cmax) of Maraviroc
Time frame:
Day 14 (0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose)
Reported as:
Median · nanogram (ng)/mL
Maximum Observed Plasma Concentration (Cmax) of Maraviroc
nanogram (ng)/mLMaraviroc+ Atazanavir / Ritonavir
Maximum Observed Plasma Concentration (Cmax) of Maraviroc650 (178 to 1490)
SecondaryMinimum Observed Plasma Concentration (Cmin) of Maraviroc
Time frame:
Day 14 (0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose)
Reported as:
Median · ng/mL
Minimum Observed Plasma Concentration (Cmin) of Maraviroc
ng/mLMaraviroc+ Atazanavir / Ritonavir
Minimum Observed Plasma Concentration (Cmin) of Maraviroc37.0 (8.4 to 92.7)
SecondaryAverage Observed Plasma Concentration (Cavg) of Maraviroc

Cavg was described as area under the plasma concentration-time profile from time zero to time 24 hours (AUC24) divided by the dosing interval (AUC24/ 24).

Time frame:
Day 14 (0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose)
Reported as:
Mean · ng/mL
Average Observed Plasma Concentration (Cavg) of Maraviroc
ng/mLMaraviroc+ Atazanavir / Ritonavir
Average Observed Plasma Concentration (Cavg) of Maraviroc185.10 ± 71.08
SecondaryChange From Baseline in Plasma log10 Viral Load at Weeks 16, 24, 48 and 96
Time frame:
Baseline, Week 16, Week 24, Week 48, Week 96
Reported as:
Mean · log10 copies/ml
Change From Baseline in Plasma log10 Viral Load at Weeks 16, 24, 48 and 96
log10 copies/mlMaraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / Tenofovir
Baseline (n= 59, 61)84982 ± 127008114827 ± 149638
Change at Week 16 (n= 54, 58)-89859.1 ± 131317.35-107684.6 ± 149476.47
Change at Week 24 (n= 56, 58)-87241.2 ± 129638.57-110498.1 ± 149836.29
Change at Week 48 (n= 53, 54)-82343.4 ± 119356.62-115582.9 ± 153705.26
Change at Week 96 (n= 49, 51)-80117.7 ± 121443.50-99662.6 ± 116525.87
SecondaryPercentage of Participants With Less Than 50 Copies/mL of HIV-1 RNA
Time frame:
Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Less Than 50 Copies/mL of HIV-1 RNA
Percentage of participantsMaraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / Tenofovir
Week 2 (n= 55, 60)0 (0 to 0)6.60 (0.35 to 12.77)
Week 4 (n= 57, 60)8.50 (1.37 to 15.58)21.30 (11.03 to 31.59)
Week 8 (n= 57, 59)47.50 (34.72 to 60.20)42.60 (30.21 to 55.03)
Week 12 (n= 55, 59)61.00 (48.57 to 73.46)62.30 (50.13 to 74.46)
Week 16 (n= 54, 58)72.90 (61.54 to 84.23)73.80 (62.73 to 84.81)
Week 20 (n= 56, 57)71.20 (59.63 to 82.74)83.61 (74.32 to 92.90)
Week 24 (n= 56, 58)81.36 (71.42 to 91.29)88.52 (80.53 to 96.52)
Week 32 (n= 55, 57)79.66 (69.39 to 89.93)88.52 (80.53 to 96.52)
Week 40 (n= 54, 55)81.36 (71.42 to 91.29)88.52 (80.53 to 96.52)
Week 48 (n= 53, 54)74.58 (63.47 to 85.69)83.61 (74.32 to 92.90)
Week 60 (n= 52, 53)67.80 (55.87 to 79.72)85.25 (76.35 to 94.15)
Week 72 (n= 52, 53)74.58 (63.47 to 85.69)81.97 (72.32 to 91.62)
Week 84 (n= 50, 52)76.27 (65.42 to 87.13)83.61 (74.32 to 92.90)
Week 96 (n= 49, 51)67.80 (55.87 to 79.72)81.97 (72.32 to 91.62)
SecondaryPercentage of Participants With Less Than 400 Copies/mL of HIV-1 RNA
Time frame:
Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Less Than 400 Copies/mL of HIV-1 RNA
Percentage of participantsMaraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / Tenofovir
Week 2 (n= 55, 60)27.12 (15.77 to 38.46)34.43 (22.50 to 46.35)
Week 4 (n= 57, 60)50.85 (38.09 to 63.60)52.46 (39.93 to 64.99)
Week 8 (n= 57, 59)79.66 (69.39 to 89.93)77.05 (66.50 to 87.60)
Week 12 (n= 55, 59)89.83 (82.12 to 97.54)88.52 (80.53 to 96.52)
Week 16 (n= 54, 58)88.14 (79.88 to 96.39)91.80 (84.92 to 98.69)
Week 20 (n= 56, 57)89.83 (82.12 to 97.54)93.44 (87.23 to 99.65)
Week 24 (n= 56, 58)91.53 (84.42 to 98.63)93.44 (87.23 to 99.65)
Week 32 (n= 55, 57)89.83 (82.12 to 97.54)93.44 (87.23 to 99.65)
Week 40 (n= 54, 55)91.53 (84.42 to 98.63)90.16 (82.69 to 97.64)
Week 48 (n= 53, 54)89.83 (82.12 to 97.54)86.89 (78.41 to 95.36)
Week 60 (n= 52, 53)86.44 (77.70 to 95.18)86.89 (78.41 to 95.36)
Week 72 (n= 52, 53)86.44 (77.70 to 95.18)85.25 (76.35 to 94.15)
Week 84 (n= 50, 52)81.36 (71.42 to 91.29)85.25 (76.35 to 94.15)
Week 96 (n= 49, 51)77.97 (67.39 to 88.54)83.61 (74.32 to 92.90)
SecondaryTime to Loss of Virological Response (TLOVR)

TLOVR (virological failure) was defined as the time from first dose of study treatment (Day 1) until the time of virologic failure using the time to loss of virologic response algorithm.

Time frame:
Baseline through Week 96
Reported as:
Mean · Days
Time to Loss of Virological Response (TLOVR)
DaysMaraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / Tenofovir
Time to Loss of Virological Response (TLOVR)436.2 ± 22.5463.8 ± 16.1
SecondaryTime-Averaged Difference (TAD) in log10 Viral Load

TAD was calculated as area under the curve of HIV divided by time period minus baseline HIV where HIV was denoted as HIV-1 RNA (log10 copies/mL).

Time frame:
Week 16, Week 24, Week 48, Week 96
Reported as:
Mean · log10 copies/mL
Time-Averaged Difference (TAD) in log10 Viral Load
log10 copies/mLMaraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / Tenofovir
Week 16-2.459 ± 0.046-2.402 ± 0.045
Week 24-2.663 ± 0.048-2.626 ± 0.046
Week 48-2.897 ± 0.046-2.868 ± 0.050
Week 96-2.998 ± 0.055-3.001 ± 0.053
SecondaryChange From Baseline in Cluster of Differentiation 4+T Lymphocyte (CD4) Cell Counts at Weeks 16, 24, 48 and 96
Time frame:
Baseline, Week 16, Week 24, Week 48, Week 96
Reported as:
Mean · cells/microliter (cells/mcL)
Change From Baseline in Cluster of Differentiation 4+T Lymphocyte (CD4) Cell Counts at Weeks 16, 24, 48 and 96
cells/microliter (cells/mcL)Maraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / Tenofovir
Baseline (n= 59, 61)357.70 ± 123.53390.00 ± 152.34
Change at Week 16 (n= 54, 58)169.60 ± 117.20139.80 ± 102.62
Change at Week 24 (n= 54, 57)188.90 ± 125.14173.30 ± 130.55
Change at Week 48 (n= 52, 53)215.70 ± 166.59226.60 ± 138.04
Change at Week 96 (n= 50, 51)287.50 ± 173.23298.50 ± 160.54
SecondaryChange From Baseline in Cluster of Differentiation 8+T Lymphocyte (CD8) Cell Count at Weeks 16, 24, 48 and 96
Time frame:
Baseline, Week 16, Week 24, Week 48, Week 96
Reported as:
Mean · cells/mcL
Change From Baseline in Cluster of Differentiation 8+T Lymphocyte (CD8) Cell Count at Weeks 16, 24, 48 and 96
cells/mcLMaraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / Tenofovir
Baseline (n= 59, 61)931.10 ± 446.261125.60 ± 735.08
Change at Week 16 (n= 54, 58)63.70 ± 290.49-153.80 ± 473.96
Change at Week 24 (n= 54, 57)6.20 ± 334.89-178.00 ± 508.75
Change at Week 48 (n= 52, 53)-76.80 ± 354.48-267.60 ± 574.22
Change at Week 96 (n= 50, 51)-63.00 ± 355.60-231.40 ± 516.99
SecondaryNumber of Participants With Genotypic Resistance

Genotypic resistance was assessed for all participants at screening and was evaluated for protease inhibitors (PIs), Nucleotide reverse transcriptase inhibitors (NRTIs), and non-NRTIs (NNRTIs) using Monogram GenoSeq and/or PhenoSenseGT assays. This was then repeated for all participants with HIV-1 viral load more than 500 copies/mL either at treatment failure or at early termination, up to Week 96.

Time frame:
Week 96 or Time of treatment failure
Reported as:
Number · Participants
Number of Participants With Genotypic Resistance
ParticipantsMaraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / Tenofovir
Number of Participants With Genotypic Resistance00
SecondaryNumber of Participants With Phenotypic Resistance

Phenotypic resistance was assessed for all participants at screening and was evaluated for PIs, NRTIs, and NNRTIs using Monogram GenoSeq and/or PhenoSenseGT assays. This was then repeated for all participants with HIV-1 viral load more than 500 copies/mL either at treatment failure or at early termination, up to Week 96.

Time frame:
Week 96 or Time of treatment failure
Reported as:
Number · Participants
Number of Participants With Phenotypic Resistance
ParticipantsMaraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / Tenofovir
Number of Participants With Phenotypic Resistance00
SecondaryNumber of Participants With HIV-1 RNA Tropism Status Using Trofile Assay

Viral tropism was determined using the trofile assay with enhanced sensitivity for participants with HIV-1 RNA greater than equal to 1000 copies/mL. The enhanced trofile assay had the sensitivity to detect 100 percent of spiked samples when C-X-C chemokine receptor type 4 {CXCR4} \[X4\]-using HIV-1 RNA represented 0.3 percent of the total viral population.

Time frame:
Baseline to Week 96 or Time of treatment Failure
Reported as:
Number · Participants
Number of Participants With HIV-1 RNA Tropism Status Using Trofile Assay
ParticipantsMaraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / Tenofovir
Baseline6061
Week 96 or Time of treatment Failure00

Adverse events

Collected over Baseline to follow-up period (28 days after the last dose of study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maraviroc+ Atazanavir / Ritonavir—13/60 (21.7%)55/60 (91.7%)
Atazanavir / Ritonavir + Emtricitabine/ Tenofovir—11/61 (18%)58/61 (95.1%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventMaraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine/ Tenofovir
AsthmaRespiratory, thoracic and mediastinal disorders2/600/61
Bronchogenic cystCongenital, familial and genetic disorders1/600/61
Intestinal perforationGastrointestinal disorders1/600/61
Anogenital wartsInfections and infestations1/601/61
CellulitisInfections and infestations1/600/61
Gastroenteritis viralInfections and infestations1/600/61
Tendon ruptureInjury, poisoning and procedural complications1/600/61
CostochondritisMusculoskeletal and connective tissue disorders1/600/61
Cognitive disorderNervous system disorders1/600/61
NephrolithiasisRenal and urinary disorders1/600/61
Most frequent other events
Showing 10 of 39
Most frequent other events
EventMaraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine/ Tenofovir
HyperbilirubinaemiaHepatobiliary disorders18/6016/61
NauseaGastrointestinal disorders6/6016/61
DiarrhoeaGastrointestinal disorders15/6014/61
Ocular icterusEye disorders13/607/61
JaundiceHepatobiliary disorders10/606/61
SinusitisInfections and infestations10/603/61
HeadacheNervous system disorders6/609/61
VomitingGastrointestinal disorders8/606/61
BronchitisInfections and infestations8/605/61
Upper respiratory tract infectionInfections and infestations8/608/61

Baseline characteristics

Age Continuous
Age Continuous(Years)Maraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / TenofovirTotal
Mean38.3 ± 10.235.3 ± 10.536.8 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Maraviroc+ Atazanavir / RitonavirAtazanavir / Ritonavir + Emtricitabine / TenofovirTotal
Female4913
Male5652108
08

Study locations

39 sites
  • Pfizer Investigational Site
    Los Angeles, California 90027, United States
  • Pfizer Investigational Site
    Los Angeles, California 90028, United States
  • Pfizer Investigational Site
    Los Angeles, California 90048, United States
  • Pfizer Investigational Site
    Los Angeles, California 90069, United States
  • Pfizer Investigational Site
    Norwalk, Connecticut 06851, United States
  • Pfizer Investigational Site
    Washington, District of Columbia 20009, United States
  • Pfizer Investigational Site
    Miami, Florida 33133, United States
  • Pfizer Investigational Site
    Miami, Florida 33136, United States
  • Pfizer Investigational Site
    Miami, Florida 33137, United States
  • Pfizer Investigational Site
    Orlando, Florida 32803, United States
  • Pfizer Investigational Site
    Pensacola, Florida 32504, United States
  • Pfizer Investigational Site
    St. Petersburg, Florida 33713, United States
  • Pfizer Investigational Site
    Tampa, Florida 33602, United States
  • Pfizer Investigational Site
    Tampa, Florida 33614, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30312, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60657, United States
  • Pfizer Investigational Site
    Springfield, Massachusetts 01107, United States
  • Pfizer Investigational Site
    Springfield, Massachusetts 01199, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68106, United States
  • Pfizer Investigational Site
    New York, New York 10003, United States
  • Pfizer Investigational Site
    Huntersville, North Carolina 28078, United States
  • Pfizer Investigational Site
    Addison, Texas 75001, United States
  • Pfizer Investigational Site
    Dallas, Texas 75204, United States
  • Pfizer Investigational Site
    Dallas, Texas 75390, United States
  • Pfizer Investigational Site
    Houston, Texas 77098, United States
  • Pfizer Investigational Site
    Spokane, Washington 99204, United States
  • Pfizer Investigational Site
    Berlin, 10243, Germany
  • Pfizer Investigational Site
    Berlin, 12157, Germany
  • Pfizer Investigational Site
    Frankfurt am Main, 60590, Germany
  • Pfizer Investigational Site
    Hamburg, 20146, Germany
  • Pfizer Investigational Site
    Koeln, 50937, Germany
  • Pfizer Investigational Site
    Muenchen, 80335, Germany
  • Pfizer Investigational Site
    L'hospitalet de Llobregat, Barcelona 08907, Spain
  • Pfizer Investigational Site
    Alicante, 03010, Spain
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    Cordoba, 14004, Spain
  • Pfizer Investigational Site
    Madrid, 28046, Spain
  • Pfizer Investigational Site
    Sevilla, 41013, Spain
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Jul 2010 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2009
First posted
Jan 22, 2009
Start
Mar 2009
Primary completionActual
Jul 2010
CompletionActual
Jul 2011
Results first posted
Nov 24, 2011
Last update
Jun 15, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00827112
Lead sponsor
ViiV Healthcare
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jan 22, 2009
Start date
Mar 2009
Primary completion
Jul 2010
Completion
Jul 2011
Results posted
Nov 24, 2011
Last update
Jun 15, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maraviroc

Start the discussion